Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 156 |
| Active Pipeline (Recruiting Now) | 44 (23) |
| Completed vs Stopped Early | 18 / 20 (12.8%) |
| Median Closed Actual Enrollment | 47 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hunan Cancer Hospital | Changsha, Hunan | 35 |
| The First Hospital of Jilin University | Changchun, Jilin | 32 |
| Henan Cancer Hospital | Zhengzhou, Henan | 27 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06900920 | A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia | Phase III | RECRUITING |
| NCT06300320 | A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease | Phase II | RECRUITING |
| NCT06351150 | Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock | Phase III | RECRUITING |
| NCT07512596 | Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ve | Phase II | RECRUITING |
| NCT07551427 | A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibr | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Chia Tai Tianqing Pharmaceutical Group Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.